{"id":"W2762638624","doi":"10.1200/jco.2017.35.15_suppl.9500","title":"A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Discontinuation; Adverse effect; Melanoma; Adjuvant; Toxicity; Neutropenia; Oncology; Phases of clinical research; Clinical endpoint; Gastroenterology; Randomized controlled trial; Surgery; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00476516,0.001973766,0.002128217,0.000566262,0.0003636608,0.001088293,0.001246276,0.001538871,0.006609414],"category_scores_gemma":[0.00216503,0.0008247477,0.001898236,0.0005834308,0.001533661,0.001016431,0.0005302817,0.003732653,0.001379216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009675337,"about_ca_system_score_gemma":0.001880349,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00078482,"about_ca_topic_score_gemma":0.001838429,"domain_scores_codex":[0.9986635,0.0009204028,0.00004978517,0.000149119,0.00007147465,0.0001457649],"domain_scores_gemma":[0.9979254,0.0005795162,0.0004693517,0.0002034603,0.00007705833,0.0007451792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9753835,0.01196371,0.0006434651,0.0001574042,0.0003649678,0.00003564156,0.00004024461,0.0003134378,0.003312952,0.0000882664,0.0004793195,0.007217162],"study_design_scores_gemma":[0.8588057,0.1369461,0.001990714,0.00001674086,0.00026877,0.00004955084,0.00002060074,0.0004322965,0.0006622707,0.0001482993,0.0006466192,0.00001229789],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842237,0.001646887,0.001095909,0.0005418544,0.0003758413,0.007825291,0.001777048,0.0001097061,0.002403935],"genre_scores_gemma":[0.9775712,0.001439086,0.003133198,0.001450495,0.000422326,0.008355016,0.002379452,0.00004805039,0.005201222],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006609414,"threshold_uncertainty_score":0.02520084,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0839105979199141,"score_gpt":0.4396343322820914,"score_spread":0.3557237343621772,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}